Parent perceptions of various treatment approaches for PANS and PANDAS
Journal of Affective Disorders · 2025-01 · 369 · 1215-1222
DOI: 10.1016/j.jad.2024.10.100 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Affective Disorders, 2025-01. Verfasst von Megan M Dailey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA. Hauptthemen laut MEDLINE: Obsessive-Compulsive Disorder, Parents, Streptococcal Infections, Autoimmune Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Pediatric autoimmune neuropsychiatric disorder (PANDAS) is characterized by sudden, dramatic onset obsessive-compulsive disorder (OCD) following a Group A Streptococcus infection. Pediatric acute neuropsychiatric syndrome (PANS) refers to sudden, dramatic onset OCD and/or restricted eating triggered by infections and other inflammatory reactions. A variety of treatments have been utilized for PANS/PANDAS; however, there is no "gold standard" intervention protocol. Parental expectations of a given treatment have been found to improve a child's overall treatment experience; however, parent attitudes towards PANS/PANDAS treatments are unknown, which was the purpose of this study. An online survey was distributed to 208 parents of children with self-reported PANS/PANDAS. Treatments were grouped together within overarching categories (i.e., psychotherapy, psychiatric/psychotropic, inflammation/infection mitigation, supplements, lifestyle changes, and surgery). Categorically, parents rated inflammation/infection mitigation interventions and lifestyle changes as most appropriate, and psychiatric/psychotropic interventions as least appropriate. At the individual level, treatments including antibiotics, non-steroidal anti-inflammatory drugs, intravenous immunoglobulin, and family counseling received ratings between "appropriate" and "extremely appropriate" Alternatively, treatments including deep brain stimulation, transcranial magnetic stimulation, antidepressant medications, and exposure and response prevention received ratings between "inappropriate" and "extremely inappropriate." Study limitations include a lack of gender and race representation in our sample. Findings indicate a need for dissemination of current, relevant research to the parent population as well as further examination of the parent experience throughout onset, diagnosis, and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
- Department of Pediatrics, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
- Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA. Electronic address: Eric.storch@bcm.edu.
Förderung
- National Institute of Child Health and Human Development
Zitieren
APA
Dailey, M. M., Colombo, G. M., Pinciotti, C. M., Sadek, S. J., Muscal, E., Saxena, K., Goodman, W. K., & Storch, E. A. (2025). Parent perceptions of various treatment approaches for PANS and PANDAS. Journal of Affective Disorders, 369, 1215-1222. https://doi.org/10.1016/j.jad.2024.10.100
Vancouver
Dailey MM, Colombo GM, Pinciotti CM, Sadek SJ, Muscal E, Saxena K, et al. Parent perceptions of various treatment approaches for PANS and PANDAS. Journal of Affective Disorders. 2025;369:1215-1222. doi:10.1016/j.jad.2024.10.100
BibTeX
@article{Dailey2025,
author = {Dailey, Megan M and Colombo, Gianna M and Pinciotti, Caitlin M and Sadek, Sarah J and Muscal, Eyal and Saxena, Kirti and Goodman, Wayne K and Storch, Eric A},
title = {Parent perceptions of various treatment approaches for PANS and PANDAS},
journal = {Journal of Affective Disorders},
year = {2025},
volume = {369},
pages = {1215--1222},
doi = {10.1016/j.jad.2024.10.100}
}
EUVIMED